Agenda

Public Workshop: Emerging Tick-Borne Diseases & Blood Safety

April 6, 2017

Ruth Kirschstein Auditorium, Natcher Building, NIH Campus, Bethesda MD

Sponsors: Center for Biologics Evaluation and Research, FDA American Association of Blood America's Blood Centers National Heart, Lung, and Blood Institute, NIH U.S. Department of Defense U.S. Department of Health and Human Services

Morning Session:

- 7:30 AM Registration Opens
- 8:30 AM Welcome Address Peter W. Marks, MD, PhD - FDA
- 8:40 AM Announcements, Objectives, and FDA Perspective on Emerging Tick-Borne Diseases David A. Leiby, PhD - FDA
- 8:55 AM Plenary Presentation on Tick-Borne Diseases Peter J. Krause, MD – Yale University
- Session 1: Biology, Epidemiology and Clinical Burden of Human Granulocytic Anaplasmosis (HGA)
- 9:30 AM Anaplasma phagocytophilum, Etiologic Agent of Human Granulocytic Anaplasmosis Cara Cherry, DVM, MPH - CDC
- 9:55 AM Clinical Aspects of Human Granulocytic Anaplasmosis J. Stephen Dumler, MD - USUHS
- 10:20 AM Coffee Break Sponsored by AABB

Session 2: Biology, Epidemiology and Clinic Burden of Other Emerging Tick-Borne Agents

- 10:50 AM Other Emerging Tick-Borne Agents Sam R. Telford III, PhD – Tufts University
- 11:20 AM One State's Perspective on Burgeoning Tick-borne Diseases Alfred DeMaria, Jr., MD – Massachusetts Department of Health
- 11:50 AM **Roundtable Discussion I** Morning Speakers; Bryan R. Spencer, MPH – American Red Cross; and Hira L. Nakhasi, PhD - FDA
- 12:20 PM Lunch

Afternoon Session:

Session 3: Transfusion Transmission

- 1:20 PM Transmission Risks Posed by Emergent Agents David A. Leiby, PhD - FDA
- 1:45 PM Incidence of Transfusion Transmission (HGA and Other Agents) Susan L. Stramer, PhD – American Red Cross

2:10 PM Coffee Break – Sponsored by America's Blood Centers

Session 4: Mitigation Efforts

- 2:40 PM Mitigating Infectious Risks of Blood Transfusion Louis M. Katz, MD – America's Blood Centers
- 3:10 PM Conceptual Framework for Test Development Raymond P. Goodrich, PhD – Colorado State University
- 3:40 PM Risk Based Decision Making: The ABO Approach Judie Leach Bennett, LLM – Canadian Blood Services

4:10 PM Roundtable Discussion II

Afternoon Speakers; CAPT Roland L. Fahie - DoD; Roger Y. Dodd, PhD – American Red Cross; and Jay S. Epstein, MD - FDA

- 5:00 PM Summary & Wrap-up David A. Leiby, PhD - FDA
- 5:15 PM Adjourn